Recursion Pharmaceuticals, Inc. Class A
As of Oct 22, 2026, Recursion Pharmaceuticals is in Stage 2, the uptrend phase, now in week 2 (since Oct 12, 2026). It closed at $3.58, 43.2% below its 52-week high and above its 200-day average, which is falling.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, d… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is RXRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RXRX among Biotechnology327th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …327 | RXRX | Stage 2 · wk 2 | 27 | −3.2% |
Recursion Pharmaceuticals: quick answers
What stage is Recursion Pharmaceuticals in?
As of Oct 22, 2026, Recursion Pharmaceuticals (RXRX) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 12, 2026 and is in week 2. What the four stages mean
Is Recursion Pharmaceuticals in an uptrend?
Yes. Recursion Pharmaceuticals is in a Stage 2 uptrend. It trades 0.9% above its 200-day average, which is falling.
How far is Recursion Pharmaceuticals from its 52-week high?
Recursion Pharmaceuticals closed at $3.58 on Oct 22, 2026, 43.2% below its 52-week high of $6.30. Its 52-week low is $2.84.
How has Recursion Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Recursion Pharmaceuticals is down 41.4% over the past year and down 14.8% so far in 2026.
Which sector and industry is Recursion Pharmaceuticals in?
Recursion Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.